{"id":"open-label-abatacept","safety":{"commonSideEffects":[{"rate":"30-40","effect":"Infections (upper respiratory, urinary tract)"},{"rate":"10-15","effect":"Headache"},{"rate":"8-12","effect":"Nausea"},{"rate":"5-10","effect":"Dizziness"},{"rate":"5-8","effect":"Hypertension"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Abatacept works by interrupting the second signal required for full T-cell activation. It consists of the extracellular domain of CTLA-4 fused to the Fc portion of IgG1, allowing it to bind CD80 and CD86 molecules on antigen-presenting cells. This prevents the interaction between these molecules and CD28 on T cells, effectively dampening the adaptive immune response and reducing production of inflammatory cytokines.","oneSentence":"Abatacept is a fusion protein that blocks T-cell costimulation by binding to CD80/CD86 on antigen-presenting cells, thereby inhibiting T-cell activation and reducing inflammatory responses.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:24:33.325Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis"},{"name":"Polyarticular juvenile idiopathic arthritis"},{"name":"Psoriatic arthritis"},{"name":"Ankylosing spondylitis"},{"name":"Systemic lupus erythematosus"}]},"trialDetails":[{"nctId":"NCT04877288","phase":"PHASE3","title":"A Study to Evaluate the Benefits and Risks of Conversion of Existing Adolescent Kidney Transplant Recipients Aged 12 to <18 Years to a Belatacept-based Immunosuppressive Regimen as Compared to Continuation of a Calcineurin Inhibitor-based Regimen, and Their Adherence to Immunosuppressive Medications","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2021-07-21","conditions":"Renal Allograft Recipients","enrollment":102},{"nctId":"NCT05621759","phase":"PHASE2","title":"Cyclophosphamide, Abatacept, and Tacrolimus for the Prevention of GvHD","status":"ACTIVE_NOT_RECRUITING","sponsor":"NYU Langone Health","startDate":"2022-09-07","conditions":"Graft Vs Host Disease","enrollment":27},{"nctId":"NCT04474847","phase":"PHASE3","title":"Abatacept for the Treatment of Giant Cell Arteritis","status":"RECRUITING","sponsor":"University of Pennsylvania","startDate":"2021-03-29","conditions":"Giant Cell Arteritis","enrollment":78},{"nctId":"NCT03841357","phase":"PHASE3","title":"Preventing Extension of Oligoarticular Juvenile Idiopathic Arthritis JIA (Limit-JIA)","status":"COMPLETED","sponsor":"Duke University","startDate":"2019-10-29","conditions":"Juvenile Idiopathic Arthritis","enrollment":121},{"nctId":"NCT05669001","phase":"PHASE2","title":"A Study of TCD601 in de Novo Renal Transplant Recipients","status":"ACTIVE_NOT_RECRUITING","sponsor":"ITB-Med LLC","startDate":"2023-12-28","conditions":"Renal Transplantation","enrollment":76},{"nctId":"NCT06008808","phase":"PHASE1","title":"Ruxolitinib With and Without CTLA-4 Ig Abatacept for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2024-05-07","conditions":"Graft Vs Host Disease, Graft-versus-host-disease, Graft Versus Host Disease","enrollment":41},{"nctId":"NCT06929039","phase":"PHASE1","title":"Open Label , Randomized, Three Arm Parallel Group Single Dose Comparative Pharmacokinetic , Safety and Immunogenicity Study in Healthy Subjects","status":"COMPLETED","sponsor":"Kashiv BioSciences, LLC","startDate":"2024-07-04","conditions":"Rheumatoid Arthritis (RA","enrollment":300},{"nctId":"NCT04046549","phase":"PHASE2","title":"A Study to Evaluate the Safety and Efficacy of Dual Costimulation Blockade With VIB4920 and Belatacept for Prophylaxis of Allograft Rejection in Adults Receiving a Kidney Transplant","status":"COMPLETED","sponsor":"Amgen","startDate":"2019-10-30","conditions":"Allografts, Rejection; Transplant, Kidney, Transplant Rejection","enrollment":25},{"nctId":"NCT03882008","phase":"PHASE4","title":"A Study to Evaluate Biomarkers to Predict Efficacy of Abatacept in Rheumatoid Arthritis","status":"COMPLETED","sponsor":"University of Washington","startDate":"2019-05-23","conditions":"Rheumatoid Arthritis","enrollment":25},{"nctId":"NCT02108860","phase":"PHASE3","title":"Abatacept for the Treatment of Relapsing, Non-Severe, Granulomatosis With Polyangiitis (Wegener's)","status":"COMPLETED","sponsor":"University of South Florida","startDate":"2015-04-25","conditions":"Granulomatosis With Polyangiitis (Wegener's), Granulomatosis With Polyangiitis, Wegener's Granulomatosis","enrollment":65},{"nctId":"NCT05981976","phase":"PHASE1","title":"A Study to Evaluate the Drug Levels of Abatacept Converted From Drug Substance by Two Different Processes in Healthy Participants","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2023-08-18","conditions":"Healthy Participants","enrollment":174},{"nctId":"NCT03086343","phase":"PHASE3","title":"A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs","status":"COMPLETED","sponsor":"AbbVie","startDate":"2017-05-09","conditions":"Rheumatoid Arthritis (RA)","enrollment":657},{"nctId":"NCT04186871","phase":"PHASE2","title":"Study to Assess Safety and Effectiveness of Branebrutinib Treatment in Participants With Active Systemic Lupus Erythematosus or Primary Sjögren's Syndrome, or Branebrutinib Treatment Followed by Open-label Abatacept Treatment in Study Participants With Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2020-01-07","conditions":"Autoimmune Disorder, Rheumatoid Arthritis, Systemic Lupus Erythematosus","enrollment":119},{"nctId":"NCT02971683","phase":"PHASE3","title":"Trial to Evaluate the Efficacy and Safety of Abatacept in Combination With Standard Therapy Compared to Standard Therapy Alone in Improving Disease Activity in Adults With Active Idiopathic Inflammatory Myopathy","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2017-05-04","conditions":"Polymyositis, Dermatomyositis, Autoimmune Necrotizing Myopathy","enrollment":149},{"nctId":"NCT03227419","phase":"PHASE4","title":"Abatacept vs Tocilizumab for the Treatment of RA in TNF Alpha Inhibitor Inadequate Responders","status":"UNKNOWN","sponsor":"Lille Catholic University","startDate":"2018-01-22","conditions":"Arthritis, Rheumatoid","enrollment":224},{"nctId":"NCT01844518","phase":"PHASE3","title":"Pharmacokinetics, Efficacy and Safety of Abatacept Administered Subcutaneously (SC) in Children and Adolescents With Active Polyarticular Juvenile Idiopathic Arthritis (pJIA) and Inadequate Response (IR) to Biologic or Non Biologic Disease Modifying Anti-rheumatic Drugs (DMARDs)","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2013-08-30","conditions":"Active Polyarticular Juvenile Idiopathic Arthritis","enrollment":219},{"nctId":"NCT04610476","phase":"PHASE3","title":"Impact of Tapering Immunosuppressants on Maintaining Minimal Disease Activity in Adult Subjects With Psoriatic Arthritis","status":"UNKNOWN","sponsor":"University of Erlangen-Nürnberg Medical School","startDate":"2020-10-19","conditions":"Psoriatic Arthritis, Withdrawal, Reduction","enrollment":270},{"nctId":"NCT02594735","phase":"PHASE4","title":"Abatacept in Juvenile Dermatomyositis","status":"COMPLETED","sponsor":"George Washington University","startDate":"2015-11","conditions":"Dermatomyositis","enrollment":10},{"nctId":"NCT01491815","phase":"PHASE4","title":"Active Conventional Therapy Compared to Three Different Biologic Treatments in Early Rheumatoid Arthritis With Subsequent Dose Reduction","status":"UNKNOWN","sponsor":"Karolinska Institutet","startDate":"2012-12-14","conditions":"Rheumatoid Arthritis","enrollment":812},{"nctId":"NCT02466581","phase":"PHASE4","title":"Dose Reduction for Early Rheumatoid Arthritis Patients With Low Disease Activity","status":"UNKNOWN","sponsor":"Karolinska Institutet","startDate":"2015-02-03","conditions":"Rheumatoid Arthritis","enrollment":25},{"nctId":"NCT01860976","phase":"PHASE3","title":"Efficacy and Safety of Subcutaneous Abatacept in Adults With Active Psoriatic Arthritis","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2013-06-17","conditions":"Psoriatic Arthritis","enrollment":489},{"nctId":"NCT05303272","phase":"PHASE4","title":"A Study to Evaluate Efficacy and Safety of Abatacept in Participants of Pemphigus Vulgaris (PV)","status":"UNKNOWN","sponsor":"Tongji Hospital","startDate":"2021-02-01","conditions":"Pemphigus Vulgaris","enrollment":60},{"nctId":"NCT02270957","phase":"PHASE2","title":"Clarification of Abatacept Effects in SLE With Integrated Biologic and Clinical Approaches","status":"COMPLETED","sponsor":"Oklahoma Medical Research Foundation","startDate":"2014-01","conditions":"Systemic Lupus Erythematosus","enrollment":66},{"nctId":"NCT02335606","phase":"","title":"Real World Effectiveness of Abatacept in Rheumatoid Arthritis Patients: a Prospective, Single-arm, Open-label, Multi-center Observational Study in Taiwan","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2014-08-06","conditions":"Rheumatoid Arthritis","enrollment":213},{"nctId":"NCT03669861","phase":"PHASE2","title":"Safety and Efficacy of Abatacept in IgG4-Related Disease","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2018-11-13","conditions":"IgG4-related Disease","enrollment":10},{"nctId":"NCT01729494","phase":"PHASE4","title":"Belatacept Early Steroid Withdrawal Trial","status":"COMPLETED","sponsor":"University of Cincinnati","startDate":"2012-09","conditions":"Renal Transplantation","enrollment":316},{"nctId":"NCT02592798","phase":"PHASE2","title":"Pilot Study to Evaluate the Safety and Efficacy of Abatacept in Adults and Children 6 Years and Older With Excessive Loss of Protein in the Urine Due to Either Focal Segmental Glomerulosclerosis (FSGS) or Minimal Change Disease (MCD)","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2016-03-09","conditions":"Nephrotic Syndrome, Focal Segmental Glomerulosclerosis, Minimal Change Disease","enrollment":36},{"nctId":"NCT01835470","phase":"PHASE3","title":"Efficacy, Safety, Pharmacokinetics and Immunogenicity Study of Abatacept Administered Intravenously to Treat Active Polyarticular-course Juvenile Idiopathic Arthritis in Japan","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2013-08-09","conditions":"Juvenile Idiopathic Arthritis","enrollment":23},{"nctId":"NCT03714022","phase":"PHASE1","title":"A Study to Evaluate the Pharmacokinetics of Abatacept Converted From Drug Substance by Two Different Processes","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2018-11-09","conditions":"Rheumatoid Arthritis","enrollment":140},{"nctId":"NCT01856257","phase":"PHASE2","title":"Open-Label Phase 2 Trial of a Steroid-Free, CNI-Free, Belatacept-Based Immunosuppressive Regimen","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2013-07","conditions":"Primary Renal Allograft Candidate, Kidney Transplantation","enrollment":71},{"nctId":"NCT02915159","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of Abatacept in Adults With Active Primary Sjögrens Syndrome","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2016-12-06","conditions":"Sjogrens Disease","enrollment":250},{"nctId":"NCT02078882","phase":"PHASE4","title":"Study of Abatacept (Orencia) to Treat Primary Biliary Cirrhosis","status":"COMPLETED","sponsor":"Christopher Bowlus, MD","startDate":"2014-09","conditions":"Primary Biliary Cirrhosis","enrollment":16},{"nctId":"NCT00739960","phase":"PHASE2","title":"Safety Study of Abatacept to Treat Refractory Sarcoidosis","status":"TERMINATED","sponsor":"University of Chicago","startDate":"2008-08","conditions":"Sarcoidosis","enrollment":1},{"nctId":"NCT02161406","phase":"PHASE2","title":"A Study of Subcutaneous Abatacept to Treat Diffuse Cutaneous Systemic Sclerosis","status":"COMPLETED","sponsor":"Dinesh Khanna, MD, MS","startDate":"2014-09","conditions":"Diffuse Cutaneous Systemic Sclerosis","enrollment":88},{"nctId":"NCT04120831","phase":"PHASE2","title":"TOLERA: Tolerance Enhancement in RA","status":"UNKNOWN","sponsor":"University of Erlangen-Nürnberg Medical School","startDate":"2019-10-07","conditions":"Rheumatoid Arthritis","enrollment":20},{"nctId":"NCT03375138","phase":"PHASE1","title":"A Study Using Healthy Volunteers Comparing Belatacept Which Has Been Manufactured By 2 Different Processes","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2017-12-04","conditions":"Healthy Volunteers","enrollment":84},{"nctId":"NCT02018042","phase":"PHASE2","title":"An Open-Label Single-Arm Clinical Trial to Evaluate The Efficacy of Abatacept in Moderate to Severe Patch Type Alopecia Areata","status":"COMPLETED","sponsor":"Columbia University","startDate":"2013-09","conditions":"Alopecia Areata","enrollment":15},{"nctId":"NCT01279954","phase":"PHASE2","title":"Abatacept in the Treatment of Uveitis","status":"COMPLETED","sponsor":"Oregon Health and Science University","startDate":"2012-01","conditions":"Uveitis","enrollment":10},{"nctId":"NCT01999868","phase":"PHASE2","title":"Efficacy of Ustekinumab Followed by Abatacept for the Treatment of Psoriasis Vulgaris","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2014-03-19","conditions":"Psoriasis","enrollment":108},{"nctId":"NCT01496417","phase":"NA","title":"Belatacept in Renal Transplantation With Intermediate Risk Maryland Aggregate Pathology Index (MAPI) Scores","status":"COMPLETED","sponsor":"University of Maryland","startDate":"2012-03","conditions":"End-Stage Renal Disease","enrollment":20},{"nctId":"NCT02281058","phase":"PHASE1","title":"Open-label Pilot Study of Abatacept for the Treatment of Vitiligo","status":"UNKNOWN","sponsor":"Brigham and Women's Hospital","startDate":"2015-01","conditions":"Vitiligo","enrollment":10},{"nctId":"NCT02078193","phase":"PHASE4","title":"Efficacy of Belatacept in Reducing DSA","status":"COMPLETED","sponsor":"East Carolina University","startDate":"2013-11","conditions":"Kidney Transplantation","enrollment":3},{"nctId":"NCT01351480","phase":"PHASE3","title":"Benefits of Injectable Abatacept Using Magnetic Resonance Imaging (MRI) in Rheumatoid Arthritis (RA) Patients","status":"COMPLETED","sponsor":"Arthritis & Rheumatic Disease Specialties Research","startDate":"2011-06","conditions":"Rheumatoid Arthritis","enrollment":34},{"nctId":"NCT00095173","phase":"PHASE3","title":"BMS-188667 in Children and Adolescents With Juvenile Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2003-12","conditions":"Juvenile Rheumatoid Arthritis","enrollment":214},{"nctId":"NCT02027298","phase":"PHASE2","title":"Abatacept for Patients With Inflammatory Arthritis Associated With Sjögren's Syndrome: an Open-Label Phase II Study","status":"WITHDRAWN","sponsor":"The Cleveland Clinic","startDate":"2013-11","conditions":"Primary Sjogren's Syndrome, Secondary Sjogren's Syndrome, Inflammatory Arthritis","enrollment":""},{"nctId":"NCT02722694","phase":"PHASE3","title":"A Phase 3 Study of Abatacept in Chinese Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate","status":"UNKNOWN","sponsor":"Jiangsu Simcere Pharmaceutical Co., Ltd.","startDate":"2016-08","conditions":"Rheumatoid Arthritis (RA)","enrollment":360},{"nctId":"NCT00886795","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of Abatacept in Subjects With Chronic Urticaria Who Have Had an Inadequate Response to Anti-histamine Therapy","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2009-05","conditions":"Urticaria","enrollment":4},{"nctId":"NCT00468208","phase":"PHASE1, PHASE2","title":"Abatacept in Treating Adults With Mild Relapsing Wegener's Granulomatosis","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2008-02","conditions":"Wegener's Granulomatosis","enrollment":20},{"nctId":"NCT01890473","phase":"PHASE1","title":"Study to Characterize the Pharmacokinetics of a Single Dose of SC Abatacept 125 mg Using the BD Autoinjector or the Prefilled Syringe","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2013-07","conditions":"Rheumatoid Arthritis","enrollment":356},{"nctId":"NCT00410410","phase":"PHASE3","title":"A Study of Abatacept in Patients With Active Ulcerative Colitis","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2006-12","conditions":"Ulcerative Colitis","enrollment":591},{"nctId":"NCT00095147","phase":"PHASE3","title":"Abatacept and Infliximab in Combination With Methotrexate in Subjects With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2005-02","conditions":"Rheumatoid Arthritis","enrollment":431},{"nctId":"NCT00547521","phase":"PHASE3","title":"Phase IIIB Subcutaneous Abatacept Monotherapy Study","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2007-12","conditions":"Rheumatoid Arthritis (RA)","enrollment":119},{"nctId":"NCT00663702","phase":"PHASE3","title":"Phase IIIB Switching From Intravenous to Subcutaneous Study","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2008-05","conditions":"Arthritis, Rheumatoid","enrollment":123},{"nctId":"NCT01846975","phase":"PHASE4","title":"Introducing a Single IV Abatacept Treatment in RA Patients Currently Receiving Weekly SC Abatacept to Simulate a Holiday","status":"COMPLETED","sponsor":"Rüdiger B. Müller","startDate":"2013-05","conditions":"Rheumatoid Arthritis","enrollment":49},{"nctId":"NCT00119678","phase":"PHASE2","title":"Abatacept in the Treatment and Prevention of Active Systemic Lupus Erythematosus (SLE) Flares in Combination With Prednisone","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2005-09","conditions":"Systemic Lupus Erythematosus","enrollment":183},{"nctId":"NCT01766050","phase":"PHASE4","title":"Study to Evaluate Effect of Belatacept on Pharmacokinetics of Inje Cocktail in Healthy Volunteers","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2013-01","conditions":"Transplant Rejection","enrollment":45},{"nctId":"NCT00455013","phase":"PHASE2","title":"A Phase II Study of Belatacept (BMS-224818) With a Steroid-free Regimen in Subjects Undergoing Kidney Transplantation","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2007-07","conditions":"Disorder Related to Renal Transplantation","enrollment":93},{"nctId":"NCT01333878","phase":"PHASE2, PHASE3","title":"Impact of Subcutaneous Abatacept in Rheumatoid Arthritis Assessing Inhibition of Structural Damage","status":"COMPLETED","sponsor":"Orrin M Troum, M.D. and Medical Associates","startDate":"2011-03","conditions":"Rheumatoid Arthritis","enrollment":12},{"nctId":"NCT01439204","phase":"PHASE1","title":"Pharmacokinetic Study to Compare the Blood Levels of Abatacept Manufactured at Lonza Biologics to the Blood Levels of Abatacept Manufactured at the Devens, Massachusetts (MA) Facility of Bristol-Myers Squibb","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2011-10","conditions":"Rheumatoid Arthritis","enrollment":223},{"nctId":"NCT00578448","phase":"PHASE2","title":"Belatacept Pharmacokinetic Trial in Renal Transplantation","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2008-03","conditions":"Renal Transplantation","enrollment":14},{"nctId":"NCT00035555","phase":"PHASE2","title":"Study Comparing the Safety and Efficacy of Belatacept With That of Cyclosporine in Patients With a Transplanted Kidney","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2001-03","conditions":"Graft Rejection, Kidney Transplantation, Renal Transplantation","enrollment":230},{"nctId":"NCT00409838","phase":"PHASE3","title":"A Phase III Study of Abatacept in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2007-04","conditions":"Rheumatoid Arthritis","enrollment":113},{"nctId":"NCT00705367","phase":"PHASE1","title":"Phase I Study in China - Tolerability of a Single Dose of Abatacept 30 mg/kg","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2008-08","conditions":"Lupus Nephritis","enrollment":13},{"nctId":"NCT00767325","phase":"PHASE3","title":"A Rheumatoid Arthritis Study to Assess Early Response to Abatacept+MTX as Defined by Improvement of Synovitis Measures by Power Doppler Ultrasonography","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2008-12","conditions":"Rheumatoid Arthritis","enrollment":104},{"nctId":"NCT00484289","phase":"PHASE3","title":"A Phase III Study of Abatacept in Japanese Subjects With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2006-12","conditions":"Rheumatoid Arthritis","enrollment":217},{"nctId":"NCT01875224","phase":"PHASE4","title":"Comparison of NODAT in Kidney Transplant Patients Receiving Belatacept Versus Standard Immunosuppression","status":"UNKNOWN","sponsor":"University of Arizona","startDate":"2013-08","conditions":"New Onset Diabetes After Transplant, Kidney Transplantation","enrollment":32},{"nctId":"NCT01272856","phase":"PHASE1","title":"Study on the Safety of Abatacept in Relapsing Polychondritis","status":"COMPLETED","sponsor":"Benaroya Research Institute","startDate":"2011-01","conditions":"Relapsing Polychondritis","enrollment":4},{"nctId":"NCT00534313","phase":"PHASE2","title":"Safety and Efficacy of Abatacept Versus Placebo in Participants With Psoriatic Arthritis","status":"TERMINATED","sponsor":"Bristol-Myers Squibb","startDate":"2007-11","conditions":"Psoriatic Arthritis","enrollment":191},{"nctId":"NCT00162266","phase":"PHASE2","title":"Abatacept With Methotrexate- Phase IIB","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2000-10","conditions":"Rheumatoid Arthritis","enrollment":524},{"nctId":"NCT00124982","phase":"PHASE3","title":"Study of Abatacept (BMS-188667) in Subjects With Active Rheumatoid Arthritis on Background Non-biologic DMARDS (Disease Modifying Antirheumatic Drugs) Who Have an Inadequate Response to Anti-TNF Therapy","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2005-04","conditions":"Rheumatoid Arthritis","enrollment":1286},{"nctId":"NCT00048568","phase":"PHASE3","title":"A Phase III Study of Abatacept (BMS-188667) in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2002-12","conditions":"Rheumatoid Arthritis","enrollment":1250},{"nctId":"NCT01339481","phase":"","title":"A Study to Assess the Receptor Occupancy of CD86 and CD80 in Subjects With Rheumatoid Arthritis Initiating Abatacept","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2011-02","conditions":"Rheumatoid Arthritis","enrollment":26},{"nctId":"NCT00048932","phase":"PHASE3","title":"A Phase III Study of BMS-188667 in Subjects With Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2002-12","conditions":"Rheumatoid Arthritis","enrollment":1795},{"nctId":"NCT00406653","phase":"PHASE3","title":"A Study of Abatacept in Patients With Active Crohn's Disease","status":"TERMINATED","sponsor":"Bristol-Myers Squibb","startDate":"2006-12","conditions":"Crohn's Disease","enrollment":451},{"nctId":"NCT00558506","phase":"PHASE2","title":"Pilot Open Label Clinical Trial With Abatacept in Ankylosing Spondylitis","status":"UNKNOWN","sponsor":"Charite University, Berlin, Germany","startDate":"2008-01","conditions":"Ankylosing Spondylitis","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":10,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Orencia","BMS-188667"],"phase":"phase_3","status":"active","brandName":"Open-label Abatacept","genericName":"Open-label Abatacept","companyName":"Bristol-Myers Squibb","companyId":"bristol-myers-squibb","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Abatacept is a fusion protein that blocks T-cell costimulation by binding to CD80/CD86 on antigen-presenting cells, thereby inhibiting T-cell activation and reducing inflammatory responses. Used for Rheumatoid arthritis, Polyarticular juvenile idiopathic arthritis, Psoriatic arthritis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}